Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1502-1508

  Clavert, Aline ^a   Le Gouill, Steven ^a,b   Brissot, Eolia ^a   Dubruille, Viviane ^a   Mahe, Beatrice ^a   Gastinne, Thomas ^a   Blin, Nicolas ^a   Chevallier, Patrice ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Ayari, Sameh ^a   Saulquin, Beatrice ^a   Moreau, Anne ^a   Moreau, Philippe ^a,b   Harousseau, Jean Luc ^a   Milpied, Noel ^a   Mohty, Mohamad ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

aggressive lymphomas; auto SCT; RIC allo SCT

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77955452652     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.497981     Document Type: Article

References (23)

1. Fisher RI. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1997;40(Suppl.): S42-S46.
2. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989;7:1018-1026.
3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
4. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406-413.
5. Takvorian T, Canellos GP, Ritz J, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987;316:1499-1505.
6. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27:426-432.
7. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991;77:649-653.
8. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992;10:1690-1695.
9. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non- Hodgkin's lymphoma. Blood 1997;90:4201-4205.
10. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17:2168-2177.
11. Mohty M, Kuentz M, Michallet M, et al. Chronic graftversus- host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002;100:3128-3134.
12. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106: 2912-2919.
13. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-1498.
14. Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of highdose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002;13:135-139.
15. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999;34:129-136.
16. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994;84:1050-1055.
17. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996;14:1291- 1296.
18. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non- Hodgkin's lymphoma. Bone Marrow Transplant 1997;19: 121-127.
19. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000;25: 1021-1028.
20. Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004;22:2419-2423.
21. Rezvani AR, Norasetthada L, Gooley T, et al. Nonmyeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008;143:395-403.
22. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12:965-972.
23. Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009;145:816-824.